In a multi-hospital analysis of individuals who experienced an allergic reaction to their first mRNA COVID-19 vaccine dose, all patients who went on to receive a second dose tolerated it without complications.
- Researchers have examined all relevant information to offer reassurance that the Pfizer-BioNTech and Moderna vaccines can be administered safely even to people with food or medication allergies
- Experts note that allergic reactions to vaccines in general are rare, with a rate of about 1.3 per 1 million people
- Individuals with a history of anaphylaxis to an injectable drug or vaccine containing polyethylene glycol or polysorbate should speak with their allergists before being vaccinated
Aleena Banerji, MD
Our guidelines are built upon the recommendations of U.S. regulatory agencies and provide clear steps to the medical community on how to safely administer both doses of the vaccine in individuals with allergic histories.
Allergy and Clinical Immunology Unit, Massachusetts General Hospital
BOSTON – Reports of possible allergic reactions to the COVID-19 vaccines produced by Pfizer-BioNTech and Moderna, both recently approved for emergency use by the U.S. Food and Drug Administration (FDA), have raised public concern. A team of experts led by allergists at Massachusetts General Hospital (MGH) has now examined all relevant information to offer reassurance that the vaccines can be administered safely even to people with food or medication allergies. The group’s review is published in the Journal of Allergy and Clinical Immunology: In Practice.
In response to accounts of potential allergic reactions in some people following COVID-19 vaccination in the United Kingdom, that country’s medical regulatory agency advised that individuals with a history of anaphylaxis to a medicine or food should avoid COVID-19 vaccination. After closer review of the data related to allergic reactions, however, the FDA recommended that the vaccines be withheld only from individuals with a history of severe allergic reactions to any component of the COVID-19 vaccine, and the Centers for Disease Control and Prevention advised that all patients be observed for 15 minutes post-vaccination by staff who can identify and manage such reactions. The U.S. agencies do not recommend that people with food or medication allergies avoid vaccination.
To provide insights from allergists’ perspectives, Aleena Banerji, MD, clinical director of the Allergy and Clinical Immunology Unit at MGH and associate professor at Harvard Medical School, and her colleagues have summarized what’s currently known about allergic reactions to vaccines like those developed against COVID-19, and they have proposed detailed advice so that individuals with different allergy histories can safely receive their first COVID-19 vaccine. They also outline steps on safely receiving the second dose in individuals who develop a reaction to their first dose of COVID-19 vaccine.
“As allergists, we want to encourage vaccination by reassuring the public that both FDA-approved COVID-19 vaccines are safe. Our guidelines are built upon the recommendations of U.S. regulatory agencies and provide clear steps to the medical community on how to safely administer both doses of the vaccine in individuals with allergic histories,” says Banerji.
The experts note that allergic reactions to vaccines are rare, with a rate of about 1.3 per 1 million people. They stress that COVID-19 vaccine clinics will be monitoring all patients for 15 to 30 minutes and can manage any allergic reactions that occur. Banerji and her co-authors recommend that individuals with a history of anaphylaxis to an injectable drug or vaccine containing polyethylene glycol or polysorbate speak with their allergists before being vaccinated. They stress that patients with severe allergies to foods, oral drugs, latex, or venom can safely receive the COVID-19 vaccines.
Co–senior authors of the review are MGH’s Kimberly G. Blumenthal, MD, MSc, and Elizabeth Phillips, MD, of Vanderbilt University Medical Center. Other co-authors include Paige G. Wickner, MD, of Brigham and Women's Hospital; Rebecca Saff, MD, PhD, Lacey B. Robinson, MD, MPH, Aidan A. Long, MD, and Anna R. Wolfson, MD, of MGH; David A. Khan, MD, of the University of Texas, Southwestern Medical Center; Cosby A. Stone Jr., MD, MPH, of Vanderbilt University Medical Center; and Paul Williams, MD, of the University of Washington School of Medicine.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
- Press Release
- Jun | 23 | 2021
Skin problems can occur in some individuals after receiving a COVID-19 vaccine. Research by led by allergists at Massachusetts General Hospital (MGH) now provides encouraging indications that the reactions are rare, and they seldom recur after receiving a second vaccine dose.
- Press Release
- Apr | 19 | 2021
At the end of 2020, allergists examined all information related to possible allergic reactions to COVID-19 vaccinations. Now the team has published updated insights based on their experience overseeing more than 65,000 employees who have become fully vaccinated since that time.
- Press Release
- Mar | 9 | 2021
Data on mRNA COVID-19 vaccinations among employees at Mass General Brigham provide reassurances of the rarity of serious reactions, and the ability to recover from them.
- Press Release
- Mar | 3 | 2021
These reactions should not discourage patients from getting the vaccine, researchers say.
- Press Release
- May | 21 | 2020
New research from Massachusetts General Hospital points to the usefulness of electronic consultations, or e-consults, during the COVID-19 pandemic.